Schafer Joshua
Known title: CCO & EVP, Bus. DevelopmentCIK: 0001945557
Schafer Joshua's purchase track record
How the stock did after each of Schafer Joshua's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since March 14, 2023
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+12.6%
3 months: +0.6%
Beat the S&P 500
33%
median -1.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/5/2023 | ZVRA | $3K | +0.6% | +17.5% | +12.9% |
| 5/19/2023 | ZVRA | $5K | -7.8% | -19.6% | +7.7% |
| 3/14/2023 | ZVRA | $9K | +21.5% | +12.6% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▼ Sell | Open Market | 10,500 | $97K | 2/3/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 35,334 | — | 1/31/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 3,375 | $30K | 1/30/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 10,500 | $83K | 2/13/2025 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 35,333 | — | 1/31/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 500 | $3K | 9/5/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,000 | $5K | 5/19/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.